89/21/2018 10:18

89/21/2018 10:18 From: Woodson C. Merrell M Uebfax Page: 6/13 Lahcorp Patient Report Patient EPSTEIN, JEFFREY DOB 0I O0'1953 Patient ID' Con trot r 33 r. 43092 Specuraen ID: 2 S7-180-: 371 -0 Date collecteck 09/14 2018 1255 oc TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB Lipoprotein (a) 20 nmol/L <75 Note: Values greater than or equal to 75 nmol/L may indicate an independent risk factor for CUD, but must be evaluated with caution when applied to non-Caucasian populations due to the influence of genetic factors on Lp(a) across ethmicities. IGP-1 Insulin-Like Growth Factor I 137 ng/mL 49 - 188 ANA w/Reflex ANA Direct Negative Negative Homocyst(e)ine, Plasma 14.9 umol/L 0.0 - 15.0 Prolactin 3.9 Low ng/mL 4.0 - 15.2 Thyroxine (T4) Free, Direct, T4,Rree(Direct) S 1.05 ng/dL 0.82 - 1.77 Cortisol 3.7 ug/dL Cortisol AM. 6.2 - 19.4 Cortisol PM 2.3 - 11.9 oaaA-sulfate 181.8 ug/dL 30.9 - 295.6 Estradiol 28.3 pg/mL 7.6 - 42.6 Roche ECLIA methodology Uric Acid Uric Acid 6.8 mg/dL 3.7 - 8.6 Please Note: Therapeutic target for gout patients: <6.0 Phosphorus 3.6 mg/dL 2.5 - 4.5 LDH 213 IU/L 121 - 224 GGT 25 IU/L 0 - 65 keyless 37 U/L 31 - 124 serritin, Serum 104 ng/mL 30 - 400 Insulin 47.2 High uIU/mIJ 2.6 - 24.9 01 02 01 01 01 01 01 01 01 01 01 01 01 01 01 01 01 Dflehus109/2006M102ET FINAL REPORT This document comaint poen and coreelentiellweldi sionnatron protected by ream and federal ten rt you an manned this document In *non plow cm] PageSd6 el9954M6LationftwyCarpornisIOMmecOMAIngs negowsilennes-exeptinattersiet too EFTA00314057